The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?

ISSN: 1875-6557 (Online)
ISSN: 1573-403X (Print)


Volume 10, 4 Issues, 2014


Download PDF Flyer




Current Cardiology Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Fei Lu
University of Minnesota Medical School
Minneapolis, MN 55455
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?

Author(s): A. John Camm MD

Affiliation: Division of Clinical Sciences, St. George's University of London, Cranmer Terrace, London, SW17 0RE, United Kingdom.

Abstract

The sudden onset of atrial fibrillation (AF) is often associated with rapid irregular palpitations, chest pain, shortness of breath and considerable anxiety. If a patient presents shortly after the onset of the arrhythmia the physician may adopt initially an expectant “wait and see” policy, perhaps with the help of mild sedation and drug therapy to reduce the ventricular rate. If the arrhythmia does not terminate spontaneously and has been present for less than 24-48 hours restoration of sinus rhythm by cardioversion should be considered. This manuscript reviews the option of electrical cardioversion versus pharmacologic and the data for, the role of, and the status of vernakalant with respect to the latter.

Keywords: Atrial fibrillation, amiodarone, cardioversion, vernakalant.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 10
Issue Number: 4
First Page: 309
Last Page: 314
Page Count: 6
DOI: 10.2174/1573403X10666140513103709
Advertisement

Related Journals



Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science